Transgene

Transgene (Euronext: TNG), part of Institut Mérieux, is a publicly traded French biopharmaceutical company focused on discovering and developing targeted immunotherapies for the treatment of cancer and infectious diseases. Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. The Company’s two lead clinical-stage programs are: TG4010 for non-small cell lung cancer and Pexa-Vec for liver cancer. The Company has several other programs in clinical and pre-clinical development. Transgene is based in Strasbourg, France, and has additional operations in Lyon, as well as satellite offices in China and the U.S.
Type
Public
HQ
Illkirch, FR
Size (employees)
146 (est)
Transgene is headquartered in Illkirch, FR

Transgene Office Locations

Transgene has offices in Illkirch, Lyon, Cambridge and Shanghai
Shanghai, CN
Rm 508, Building 2 4633, Pusan Road Kangqiao Industrial Park, Pudong Shanghai
Cambridge, US
802 355 Main St
Lyon, FR
321 Avenue Jean Jaurès

Transgene Financials and Metrics

Transgene Financials

EUR

Market capitalization (17-Oct-2017)

188.5 m

Closing share price (17-Oct-2017)

3.3
Transgene's current market capitalization is €188.5 m.
Show all financial metrics

Transgene Market Value History

Traffic Overview of Transgene

Transgene Online and Social Media Presence

Transgene News and Updates

Agricultural Biotechnology Market: Global Key Players, Trends, Share, Industry Size, Growth, Opportunities, Forecast To 2022

Global Agricultural Biotechnology market is accounted for $20.08 billion in 2015 and is expected to reach $39.5 billion by 2022 growing at a CAGR of 10.1% from 2015 to 2022 Posted via Industry Today. Follow us on Twitter @IndustryToday

Transgene Company Life and Culture

You may also be interested in